Novartis releases new data across oncology and haematology pipelines
Ella Day | May 21, 2025 | News story | Research and Development | ASCO, EHA, Haematology, Novartis, Oncology, oncology
Novartis has announced it will present new data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place between 30 May and 3 June, and the European Haematology Association (EHA) 2025 Congress taking place between 13 and 16 June. This will feature findings from the company’s oncology pipeline as well as its haematology pipelines at the EHA.
“At ASCO and EHA, we will present new data on priority medicines from our oncology and haematology portfolio, as well as updates from our pipeline and our radioligand therapy research,” said Shreeram Aradhye, president, development and chief medical officer of Novartis.
The company will highlight a number of standout developments. It will present data from the NATALEE trial evaluating Kisqali (ribociclib) in pre-menopausal early breast cancer patients and compare this with real-world findings on the risk of recurrence in Black women with HR+/HER2- early breast cancer. Also part of its oncology research, it will discuss results from ASC4START comparing Scemblix (asciminib) versuss. nilotinib in newly diagnosed chronic phase chronic myeloid leukaemia (CML-CP).
In relation to its haematology pipeline, highlights at the EHA will include new data from research on Fabhalta (iptacopan) in paroxysmal nocturnal haemoglobinuria (PNH) and on the CAR-T therapy YTB323 study in large B-cell lymphoma.
“The breadth of our oncology and haematology portfolio, anchored by Kisqali, Pluvicto [lutetium Lu 177 vipivotide tetraxetan], Scemblix and Fabhalta, demonstrates our leadership in both solid tumours and haematologic diseases,” added Aradhye.
Partnerships with advocacy groups, including the Alliance for Breast Cancer Policy and ZERO Prostate Cancer will also be showcased at the events, aligning with Novartis’s commitment to patient-centred policy and public health awareness.
Ella Day
21/5/25
Related Content
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …
